5Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer,1981, 48: 2485-2492.
6Dhein J, Walczak H, Baumler C, et al. Autocrine T-Cell Suicide mediated by APO-1/(Fas/CD95). Nature, 1995, 373 : 438-441.
7Navikas V, Link J, Palasik W, et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol, 1995, 41: 171-178.
8Shiono H, Fujii Y, Okumura M, et al. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol. 1997. 27: 805-809.
9Onodera J, Nakamura S, Nagano 1, et al. Upregulation of Bcl-2 protein in the myasthenic thymus. Ann Neurol, 1996, 39: 521-528.
5Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg,2008,86 (2) :673-684.
6Kondo K. Optimal therapy for thymoma. J Clin Invest, 2008,55 (1-2) : 17-28.
7Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer, 1981,48 ( 11 ) :2485-2492.
8Rosai J, Sobin L. Histological typing of tumours of the thymus. In : World Health Organization, ed. International histological classification of tumours. Heidelberg: Springer, 1999 : 1-16.
